| 1. | Breast |
| a. | Needle core biopsy diagnosis: when to excise and when not to excise | |
| b. | Basal cell phenotype breast cancer (see Hereditary adult tumors) | |
| c. | Columnar cell lesions | |
| d. | Her2-neu testing guidelines | |
| e. | Sentinel lymph node biopsy | |
| f. | Immunohistochemistry in breast pathology |
| i. | Myoepithelial markers and stromal invasion | ||
| ii. | Markers of lobular/ductal differentiation |
| References |
| 2. | CNS |
| a. | Diffuse gliomas: morphologic features and molecular markers |
| i. | 1p/19q deletions in oligodendroglioma | ||
| ii. | EGFR amplification in glioblastoma multiforme |
| References |
| 3. | Cytology |
| a. | Guidelines for cervical cytology screening and management and HPV testing: 2006 ASCCP Consensus Guidelines for management of abnormal cervical cytology |
| i. | Appropriate use of HPV testing for screening and triage |
| b. | Bethesda system of reporting of GYN cytology | |
| c. | Endoscopic ultrasound-guided FNA diagnosis |
| References |
| 4. | GI |
| a. | Alimentary tract |
| i. | Serrated polyp, sessile serrated adenomas; serrated pathway for adenocarcinoma, hereditary non-polyposis carcinoma | ||
| ii. | Gastrointestinal stromal tumor and its mimics | ||
| iii. | Esophagitis, eosinophilic esophagitis, reflux | ||
| iv. | Microscopic colitis | ||
| v. | Dysplasia in Barrett’s esophagus and inflammatory bowel disease | ||
| vi. | Sprue, diagnosis with normal villous architecture, but with increased mucosal lymphocytes (lymphocytic enteritis) |
| b. | Liver |
| i. | Grading and staging of chronic hepatitis | ||
| ii. | Steatohepatitis, NASH |
| c. | Pancreas |
| i. | Classification of pancreatic intraepithelial neoplasia, PANin | ||
| ii. | Intraductal papillary mucinous tumors | ||
| iii. | Mucinous cystic tumors | ||
| iv. | Autoimmune pancreatitis | ||
| v. | Pancreatic endocrine neoplasms: diagnosis and prognosis |
| References |
| 5. | GU |
| a. | Prostate |
| i. | Update on Gleason grading of prostate cancer | ||
| ii. | Immunohistochemistry in diagnosis of adenocarcinoma: Amicar, basal cell markers | ||
| iii. | Criteria for prostatic adenocarcinoma, ASAP, PIN | ||
| iv. | Newly described patterns of adenocarcinoma which mimic benign disease which include foamy gland carcinoma, atrophic carcinoma and pseudohyperplastic carcinoma | ||
| v. | Post-treatment diagnosis of prostate cancer |
| b. | Bladder |
| i. | Histologic variants of urothelial carcinoma, nested urothelial carcinoma, plasmacytoid, micropapillary, lymphoepithelioma-like variants | ||
| ii. | Spindle cell proliferations | ||
| iii. | WHO/ISUP classification of urothelial tumors |
| c. | Kidney |
| i. | Cytogenetics of renal neoplasms | ||
| ii. |
Classification of renal neoplasms Use of immunohistochemistry in renal neoplasms | ||
| iii. | Staging of renal cell carcinoma and renal sinus involvement |
| d. | Testis |
| i. | Immunohistochemistry in diagnosis of testicular neoplasms PLAP, OCT 3 /4, inhibin, c-kit, CD30 |
| References |
| 6. | GYN |
| a. | Pseudomyxoma peritonei | |
| b. | Mucinous ovarian tumors | |
| c. | Serous borderline tumors and significance of micropapillary pattern | |
| d. | New concepts in ovarian and pelvic serous carcinogenesis |
| i. | Different molecular pathways in low grade serous carcinoma versus high grade serous carcinoma | ||
| ii. | The relationship between intraepithelial carcinoma of the fallopian tube and pelvic serous carcinomas |
| e. | Diagnostic immunohistochemistry/biomarkers |
| i. | P16/Ki-67 in HPV associated lesions | ||
| ii. | WT-1 in ovarian/peritoneal serous tumors |
| f. | Prognostic parameters in endometrial carcinoma |
| References |
| 7. | Hematopathology |
| a. | Standardized WHO nomenclature (2001) for lymphoma, leukemia, myeloproliferative disorders, myelodysplastic disorders, plasma cell neoplasms | |
| b. | Minimal residual disease in acute leukemia | |
| c. | Recently described lymphomas |
| i. | Primary effusion lymphoma | ||
| ii. | Plasmablastic lymphoma |
| d. | Ancillary techniques |
| i. | Transcription factors in lymphomas and leukemias | ||
| ii. | Molecular markers, JAK-2 |
| References |
| 8. | Hereditary Adult Tumors: current concepts |
| a. | BRCA 1 and 2 |
| i. | Breast – morphologic features and basal phenotype | ||
| ii. | Ovary – morphologic features and risk | ||
| iii. | Fallopian tube – morphologic features and handling of specimens for prophylactic bilateral salpingo-oophorectomies |
| b. | Hereditary Non-Polyposis colon cancer (HNPCC) and MSI | |
| c. | Familial Adenomatous Polyposis and other polyposis syndromes |
| References |
| 9. | Pulmonary |
| a. | Bronchoalveolar carcinoma and concept of “in-situ” adenocarcinoma | |
| b. | Current concepts in Interstitial lung disease | |
| c. | Important histologic parameters in staging and prognosis of lung cancer | |
| d. | Carcinoma vs mesothelioma vs pleuritis |
| References |
| 10. | QA in anatomic pathology |
| a. | Use of standardized pathology protocols | |
| b. | Error in anatomic pathology | |
| c. | Critical diagnoses in anatomic pathology (critical values) |
| References |
| 11. | Skin |
| a. | Desmoplastic melanoma | |
| b. | Sentinel lymph node biopsy |
| References |
| 12. | Soft Tissue |
| a. | New concepts/update in classification |
| i. | Pleomorphic undifferentiated sarcoma ( MFH) | ||
| ii. | Hemangiopericytoma-Solitary Fibrous tumor | ||
| iii. | Borderline vascular tumors | ||
| iv. | Atypical lipomatous tumor-Well differentiated liposarcoma |
| b. | Needle Biopsy interpretation: Limitations and Grading | |
| c. | New diagnostic markers |
| i. | MDM2/CDK4 ( well differentiated liposarcoma) | ||
| ii. | LANA-1 (Kaposi sarcoma) | ||
| iii. | TFE3 (alveolar soft part sarcoma) | ||
| iv. | WT1 (desmoplastic small round cell tumor) | ||
| v. | beta-catenin (fibromatosis) | ||
| vi. | ALK (inflammatory myofibroblastic tumor) |
| d. | Translocation-associated sarcomas vs. Non translocation sarcomas |
| i. | Biological and histological differences | ||
| ii. | Molecular genetic identification of soft tissue tumors |
| e. | Recent entities |
| i. | Perineurioma | ||
| ii. | PEComa | ||
| iii. | Acraliv myxoinflammatory fibroblastic sarcoma | ||
| iv. | Low grade fibromyxoid sarcoma | ||
| v. | Desmoplastic small round cell tumor |
| References |
| 13. | Molecular |
| a. | Gene probe technology in tumor pathology | |
| b. | Molecular markers in relation to chemotherapy: GIST | |
| c. | Targeted therapies |
| General References |